新冠病毒肺炎患者中补体C5抑制——一个有前景的靶点？ - Suppr | 超能文献

Complement C5 inhibition in patients with COVID-19 - a promising target?

作者信息

Peffault de Latour Regis, Bergeron Anne, Lengline Etienne, Dupont Thibault, Marchal Armance, Galicier Lionel, de Castro Nathalie, Bondeelle Louise, Darmon Michael, Dupin Clairelyne, Dumas Guillaume, Leguen Pierre, Madelaine Isabelle, Chevret Sylvie, Molina Jean-Michel, Azoulay Elie, Fremeaux-Bacchi Veronique

机构信息

Saint Louis Hospital.

Saint-Louis Hospital.

出版信息

Haematologica. 2020 Dec 1;105(12):2847-2850. doi: 10.3324/haematol.2020.260117.

DOI:10.3324/haematol.2020.260117

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7716359/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf69/7716359/d1cdb50983f3/1052847.fig1.jpg

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Complement C5 inhibition in patients with COVID-19 - a promising target?

Haematologica. 2020 Dec 1;105(12):2847-2850. doi: 10.3324/haematol.2020.260117.

2

Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.

Clin Immunol. 2020 Nov;220:108598. doi: 10.1016/j.clim.2020.108598. Epub 2020 Sep 19.

3

COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience.

Br J Haematol. 2020 Oct;191(1):e1-e4. doi: 10.1111/bjh.17097. Epub 2020 Sep 18.

4

Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).

Br J Haematol. 2020 Jan;188(2):334-337. doi: 10.1111/bjh.16305. Epub 2019 Dec 16.

5

[Complement-Mediated Mechanism and Complement Inhibitors in Guillain-Barré Syndrome].

Brain Nerve. 2019 Jun;71(6):581-587. doi: 10.11477/mf.1416201319.

6

Drugs that inhibit complement.

Transfus Apher Sci. 2012 Feb;46(1):87-92. doi: 10.1016/j.transci.2011.11.012. Epub 2011 Dec 13.

7

COVID-19 Updates: Monoclonal Antibodies for COVID-19.

Med Lett Drugs Ther. 2022 Jan 24;64(1642):16.

8

Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation.

Transplantation. 2013 Aug 27;96(4):e26-9. doi: 10.1097/TP.0b013e31829d388d.

9

C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19.

J Clin Immunol. 2021 May;41(4):729-732. doi: 10.1007/s10875-021-00972-1. Epub 2021 Jan 21.

10

Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.

Am J Case Rep. 2020 Sep 12;21:e927418. doi: 10.12659/AJCR.927418.

引用本文的文献

1

Enhanced complement activation and MAC formation accelerates severe COVID-19.

Cell Mol Life Sci. 2024 Sep 16;81(1):405. doi: 10.1007/s00018-024-05430-w.

2

Complement system activation: bridging physiology, pathophysiology, and therapy.

Intensive Care Med. 2024 Nov;50(11):1791-1803. doi: 10.1007/s00134-024-07611-4. Epub 2024 Sep 10.

3

Emerging role of complement in COVID-19 and other respiratory virus diseases.

Cell Mol Life Sci. 2024 Feb 18;81(1):94. doi: 10.1007/s00018-024-05157-8.

4

COVID-19 vaccination prevents a more severe course and treatment with complement inhibitors reduce worsening hemolysis during the Omicron pandemic in patients with PNH: a single-center study.

Ann Med. 2023;55(2):2274510. doi: 10.1080/07853890.2023.2274510. Epub 2024 Jan 1.

5

Mechanisms of COVID-19 Associated Pulmonary Thrombosis: A Narrative Review.

Biomedicines. 2023 Mar 16;11(3):929. doi: 10.3390/biomedicines11030929.

6

Levels of Complement Components in Children With Acute COVID-19 or Multisystem Inflammatory Syndrome.

JAMA Netw Open. 2023 Mar 1;6(3):e231713. doi: 10.1001/jamanetworkopen.2023.1713.

7

Factor H autoantibodies contribute to complement dysregulation in multisystem inflammatory syndrome in children (MIS-C).

Am J Hematol. 2023 May;98(5):E98-E101. doi: 10.1002/ajh.26868. Epub 2023 Feb 13.

8

COVID-19 vaccination and Atypical hemolytic uremic syndrome.

Front Immunol. 2022 Dec 1;13:1056153. doi: 10.3389/fimmu.2022.1056153. eCollection 2022.

9

Complement activation predicts negative outcomes in COVID-19: The experience from Northen Italian patients.

Autoimmun Rev. 2023 Jan;22(1):103232. doi: 10.1016/j.autrev.2022.103232. Epub 2022 Nov 19.

10

Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review.

World J Exp Med. 2022 Jul 20;12(4):53-67. doi: 10.5493/wjem.v12.i4.53.